Patents Assigned to Intezyne Technologies, Inc.
-
Patent number: 12173087Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imagable contrast agent and/or anti-cancer agent) selectively to the tumor cell.Type: GrantFiled: January 24, 2022Date of Patent: December 24, 2024Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Intezyne Technologies Inc., Arizona Board of Regents on Behalf of The University of Arizona, Board of Regents, The University of Texas SystemInventors: Robert J. Gillies, David L. Morse, Natalie M. Barkey, Kevin N. Sill, Josef Vagner, Narges K. Tafreshi, Jonathan L. Sessler, Christian Preihs, Victor J. Hruby
-
Patent number: 11230568Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.Type: GrantFiled: June 24, 2019Date of Patent: January 25, 2022Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., INTEZYNE TECHNOLOGIES INC., ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, BOARD OF REGENTS, UNTVERSITY OF TEXAS SYSTEMInventors: Robert J. Gillies, David L. Morse, Natalie M. Barkey, Kevin N. Sill, Josef Vagner, Narges K. Tafreshi, Jonathan L. Sessler, Christian Preihs, Victor J. Hruby
-
Patent number: 10857147Abstract: The present invention provides SN-38 compositions for treating cancer.Type: GrantFiled: November 19, 2018Date of Patent: December 8, 2020Assignee: Intezyne Technologies, Inc.Inventors: Kevin N. Sill, Adam Carie
-
Patent number: 10329326Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.Type: GrantFiled: September 12, 2016Date of Patent: June 25, 2019Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM, H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., INTEZYNE TECHNOLOGIES INC.Inventors: Robert J. Gillies, David L. Morse, Natalie M. Barkey, Kevin N. Sill, Josef Vagner, Narges K. Tafreshi, Jonathan L. Sessler, Christian Preihs, Victor J. Hruby
-
Patent number: 10047197Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.Type: GrantFiled: September 28, 2016Date of Patent: August 14, 2018Assignee: Intezyne Technologies, Inc.Inventors: Kevin Sill, Adam Carie
-
Patent number: 9944752Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.Type: GrantFiled: March 10, 2016Date of Patent: April 17, 2018Assignee: Intezyne Technologies, Inc.Inventors: Kevin Sill, Tomas Vojkovsky, Adam Carie, Joseph Edward Semple, Hooshmand Sheshbaradaran
-
Patent number: 9944754Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.Type: GrantFiled: September 28, 2016Date of Patent: April 17, 2018Assignee: Intezyne Technologies, Inc.Inventors: Kevin Sill, Joseph Edward Semple, Tomas Vojkovsky
-
Patent number: 9499665Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.Type: GrantFiled: April 23, 2015Date of Patent: November 22, 2016Assignee: Intezyne Technologies, Inc.Inventors: Kevin Sill, Tomas Vojkovsky, Adam Carie
-
Patent number: 9441013Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.Type: GrantFiled: May 17, 2012Date of Patent: September 13, 2016Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., INTEZYNE TECHNOLOGIES INC, ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEMInventors: Robert J. Gillies, David L. Morse, Natalie M. Barkey, Kevin N. Sill, Josef Vagner, Narges K. Tafreshi, Jonathan L. Sessler, Christian Preihs, Victor J. Hruby
-
Patent number: 9089578Abstract: Methods and compositions for treating neuroendocrine tumors are disclosed.Type: GrantFiled: April 25, 2013Date of Patent: July 28, 2015Assignee: Intezyne Technologies, Inc.Inventors: Hooshmand Sheshbaradaran, William McCulloch
-
Patent number: 9078930Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.Type: GrantFiled: March 15, 2013Date of Patent: July 14, 2015Assignee: Intezyne Technologies, Inc.Inventors: Kevin Sill, Tomas Vojkovsky, Adam Carie
-
Patent number: 8980326Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.Type: GrantFiled: September 1, 2010Date of Patent: March 17, 2015Assignee: Intezyne Technologies, Inc.Inventors: Kevin N. Sill, Habib Skaff, Kurt Breitenkamp
-
Publication number: 20140302607Abstract: The present invention provides a methodology for transfecting cells in vitro. In particular, cationic polymers and polynucleotide containing polyplexes comprising such polymers are provided.Type: ApplicationFiled: January 27, 2014Publication date: October 9, 2014Applicant: Intezyne Technologies, Inc.Inventor: Janni Mirosevich
-
Publication number: 20140271885Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.Type: ApplicationFiled: February 11, 2014Publication date: September 18, 2014Applicant: Intezyne Technologies, Inc.Inventors: Kevin Sill, Tomas Vojkovsky
-
Patent number: 8779008Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.Type: GrantFiled: December 19, 2012Date of Patent: July 15, 2014Assignee: Intezyne Technologies, Inc.Inventors: Kurt Breitenkamp, Kevin N. Sill, Habib Skaff, Rebecca Breitenkamp
-
Patent number: 8747904Abstract: The present invention provides micelles having a polynucleotide encapsulated therein, the micelle comprising copolymers comprising hydrophobic moieties in a cationic complexing block. The invention further provides methods of preparing and using said micelles, and compositions thereof.Type: GrantFiled: August 21, 2012Date of Patent: June 10, 2014Assignee: Intezyne Technologies, Inc.Inventors: Janni Mirosevich, Gregoire Cardoen, Kevin N. Sill, Habib Skaff
-
Publication number: 20140127271Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.Type: ApplicationFiled: September 16, 2013Publication date: May 8, 2014Applicant: Intezyne Technologies, Inc.Inventors: Kevin Sill, Hooshmand Sheshbaradaran
-
Publication number: 20140113879Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.Type: ApplicationFiled: September 16, 2013Publication date: April 24, 2014Applicant: Intezyne Technologies, Inc.Inventors: Adam Carie, Kevin Sill
-
Publication number: 20140112873Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.Type: ApplicationFiled: May 17, 2012Publication date: April 24, 2014Applicants: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM, ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, INTEZYNE TECHNOLOGIES INC.Inventors: Robert J. Gillies, David L. Morse, Natalie M. Barkey, Kevin N. Sill, Josef Vagner, Narges K. Tafreshi, Jonathan L. Sessler, Christian Preihs, Victor J. Hruby
-
Publication number: 20140114051Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.Type: ApplicationFiled: September 16, 2013Publication date: April 24, 2014Applicant: Intezyne Technologies, Inc.Inventor: Joseph Edward Semple